Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02356653 | Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC(ExpMACs) | recruiting | Early Phase 1 | 100 | Children's Hospital of PhiladelphiaOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03334500 | Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer | active not recruiting | Early Phase 1 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 20, 2026 |
| clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07235280 | Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma | recruiting | Early Phase 1 | 48 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07420010 | An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors. | not yet recruiting | Early Phase 1 | 24 | Weijia Fang, MDOTHER | 0 | Feb 19, 2026 | clinicaltrials |
| NCT01858025 | Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma | completed | Early Phase 1 | 25 | Massachusetts General HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03445858 | Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | completed | Early Phase 1 | 22 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07416240 | Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer. | recruiting | Early Phase 1 | 10 | Hainan Cancer HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03771651 | Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube | active not recruiting | Early Phase 1 | 18 | University of OklahomaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03970226 | Tocilizumab in Children With ACP | active not recruiting | Early Phase 1 | 9 | University of Colorado, DenverOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04512716 | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | recruiting | Early Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07414316 | A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. | recruiting | Early Phase 1 | 10 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03861676 | Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT | recruiting | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05683964 | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | active not recruiting | Early Phase 1 | 9 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07409766 | A Phase I Platform Study of Target-Based Screened CAR-Macrophages for the Treatment of Advanced Malignant Tumors | not yet recruiting | Early Phase 1 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04265872 | Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC | recruiting | Early Phase 1 | 20 | Baylor Research InstituteOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05160597 | Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy | active not recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05493566 | Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer | recruiting | Early Phase 1 | 15 | Emory UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06475664 | Colorectal Cancer Legal and Administrative Burden Support: A Pilot Clinical Trial | completed | Early Phase 1 | 20 | University of MinnesotaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06213298 | Effect of Kava on Anxiety and Stress in Cancer Survivors | suspended | Early Phase 1 | 43 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07234721 | SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma(SL4903) | not yet recruiting | Early Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 10, 2026 | clinicaltrials |
| NCT07399444 | A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）(LB2505-0001) | not yet recruiting | Early Phase 1 | 38 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04173104 | PET and MRI Imaging of Brain Tumors Using [18F]PARPi | completed | Early Phase 1 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05333874 | CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage | active not recruiting | Early Phase 1 | 34 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT02724202 | Curcumin in Combination With 5FU for Colon Cancer | terminated | Early Phase 1 | 15 | Baylor Research InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03543969 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | active not recruiting | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05093335 | In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05316116 | Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) | terminated | Early Phase 1 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05620342 | Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | recruiting | Early Phase 1 | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07236177 | B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.(B-GLUCANCER2) | recruiting | Early Phase 1 | 220 | Poitiers University HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04457089 | Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer | completed | Early Phase 1 | 18 | Marc GoodmanOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05800405 | Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Early Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06408298 | HCQ in Resectable Localized Prostate Cancer | recruiting | Early Phase 1 | 20 | Lionel.D.Lewis, MDOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07327632 | This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors | recruiting | Early Phase 1 | 300 | Innovent Biologics Technology Limited (Shanghai R&D Center)INDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04044872 | Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity | terminated | Early Phase 1 | 3 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07381582 | Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(161Tb-LNC1011) | not yet recruiting | Early Phase 1 | 15 | Peking Union Medical College HospitalOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06639191 | [177Lu]Lu-AKIR001 First-in-human Study(AKIR001) | recruiting | Early Phase 1 | 15 | Karolinska University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT01881048 | Window of Opportunity Study Targeting the Inflammatory Milieu | completed | Early Phase 1 | 42 | University of Colorado, DenverOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07371247 | Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy | enrolling by invitation | Early Phase 1 | 65 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT03321045 | Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness | recruiting | Early Phase 1 | 10 | University of Alabama at BirminghamOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05553782 | Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers | recruiting | Early Phase 1 | 30 | Brigham and Women's HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05921253 | Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy(OU-SCC-NCAN) | recruiting | Early Phase 1 | 104 | University of OklahomaOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04825275 | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial | terminated | Early Phase 1 | 7 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06499090 | Mirtazapine for Acute and Chronic Post Mastectomy Pain | completed | Early Phase 1 | 62 | Assiut UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07108140 | Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors | terminated | Early Phase 1 | 5 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06922825 | Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients | withdrawn | Early Phase 1 | 0 | Eben RosenthalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07242417 | TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors | recruiting | Early Phase 1 | 30 | Beijing GoBroad HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07356466 | Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(FUGES032) | enrolling by invitation | Early Phase 1 | 100 | Fujian Medical UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07185490 | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(IASO104) | not yet recruiting | Early Phase 1 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07352345 | Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 150 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 20, 2026source: clinicaltrials